Press release - Oslo, Norway, October 6, 2023: Photocure ASA, The Bladder Cancer
Company, announces the publication of "A cost-consequences and budget impact
analysis of blue light-guided cystoscopy with Hexvix[®] in patients diagnosed
with non-muscle-invasive bladder cancer in France" in the peer-reviewed
international Journal of Medical Economics this week. This health economic
analysis aims to assess the financial impact of widely adopting Blue Light
Cystoscopy (BLC[®]) as recommended in the French ccAFU guidelines. A budget
impact model (BIM) was developed, that simulates the overall costs of
implementing a range of strategies involving the use of BLC, with analyses then
undertaken to determine the cost consequences for individual hospitals if
implementing the recommended management approach.

The analysis, led by Dr. Jonathan Belsey, [Health Economist & Managing Director
of JB Medical Ltd), details that clinical evidence, such as published in the
recent Cochrane review, supports the benefits of BLC over White Light
Cystoscopies (WLC) alone on the detection of bladder tumors and time to first
recurrence as well as an extended time to disease progression in patients
managed with BLC-assisted TURBT*.

The most recent ccAFU (Comité de cancérologie de l'Association française
d'urologie) guidelines recommend the use of BLC in a number of different
positions in the care pathway for NMIBC. The study authors explain: "The health
economic impact of this strategy has been evaluated using a cost-utility
analysis, from the perspective of the French healthcare system, and was found to
be dominant over WLC - meaning that its use results in better outcomes and lower
costs overall. Despite the existence of a clear clinical and economic evidence
base, however, concerns around the potential budgetary impact of the widespread
adoption of BLC have led to a degree of reluctance to adopt the technology."

ccAFU guidelines are detailed as follows: ".the French guidelines make strong
recommendations that BLC should be used: for the initial diagnostic TURBT in all
but the smallest unifocal tumors